What Is in Dupixent? Active and Inactive Ingredients

Dupixent contains one active ingredient, dupilumab, a lab-engineered antibody protein, along with a short list of inactive ingredients that keep the protein stable and injectable. The inactive ingredients are L-arginine hydrochloride, L-histidine, L-histidine hydrochloride monohydrate, polysorbate 80, sucrose, and water for injection. Understanding what each component does and why it is there can help you make sense of storage instructions, injection-site reactions, and other practical questions about using the medication.

The Active Ingredient

Dupilumab is a humanized monoclonal antibody, which means it is a protein designed in a laboratory to mimic a natural immune-system molecule but engineered to target one specific thing. In this case, dupilumab locks onto a receptor on cells called the interleukin-4 receptor alpha subunit. That receptor is a shared docking point for two chemical messengers, interleukin-4 (IL-4) and interleukin-13 (IL-13), that are central drivers of what scientists call type 2 inflammation.1PubMed Central. Dupilumab: Mechanism of action, clinical, and translational science By physically sitting on that receptor and preventing IL-4 and IL-13 from binding, dupilumab dials down the inflammatory chain reaction responsible for conditions like atopic dermatitis (eczema), asthma, and chronic rhinosinusitis with nasal polyps.

The antibody itself belongs to a class called IgG4, which is important because IgG4 antibodies are less likely to trigger secondary immune responses in the body compared to other antibody classes. The protein targets both the type 1 and type 2 forms of the IL-4 receptor complex, which is why it can block both IL-4 and IL-13 at the same time rather than needing separate drugs for each.2PubMed Central. Mechanisms of Dupilumab That dual blockade is the reason Dupixent works across multiple type-2-driven diseases rather than being limited to just one condition.

The Inactive Ingredients and What They Do

Dupilumab is a large, fragile protein. Without the right surrounding chemistry, it would unfold, clump together, or break down long before it reached your body. Each of the six inactive ingredients (known formally as excipients) plays a specific role in keeping the protein intact and the solution safe to inject.

  • L-histidine and L-histidine hydrochloride monohydrate: These two work together as a buffering system, maintaining the pH of the solution in a narrow range where the protein is most stable. If the pH drifted too far in either direction, the antibody’s shape would distort and it would lose its ability to bind its target.
  • L-arginine hydrochloride: This amino acid salt serves primarily as a stabilizer. In high-concentration protein formulations like Dupixent, arginine helps prevent the antibody molecules from sticking to one another and clumping, and it also reduces the viscosity of the solution so it can flow through a thin needle.
  • Sucrose: The sugar acts as a cryoprotectant and stabilizer, shielding the antibody during temperature fluctuations and storage. Sucrose molecules essentially crowd around the protein and help it maintain its three-dimensional shape.
  • Polysorbate 80: This is a surfactant, meaning it reduces surface tension at the air-liquid interface inside the syringe or vial. Without it, the antibody molecules would migrate to surfaces and air bubbles, where they are prone to unfolding and forming aggregates.
  • Water for injection: The purified water base that everything is dissolved in, manufactured to strict standards that ensure it is free of contaminants and pyrogens (substances that could cause a fever).

Arginine is worth a closer look because it is a relatively recent staple in biologic formulations. Over the past decade, it has become one of the most commonly used excipients in injectable antibody drugs because of its ability to suppress protein-protein interactions, reduce aggregation, and lower viscosity in concentrated solutions.3PubMed Central. Effects of arginine in therapeutic protein formulations: a decade review and perspectives For a drug like Dupixent, which is injected at a concentration of 150 milligrams per milliliter, viscosity matters because a thicker solution is harder to push through the needle and more painful to inject.

Why the List Is So Short

If you have ever turned over a bottle of over-the-counter pain reliever and read a paragraph-long list of inactive ingredients, Dupixent’s handful may surprise you. Research examining biologic drug formulations found that a typical biologic product contains an average of about four to five excipients, roughly half the number found in a standard oral medication.4PubMed Central. Biologic excipients: Importance of clinical awareness of inactive ingredients The reason is straightforward: oral drugs need coatings, fillers, binders, coloring agents, and flavorings to survive the digestive system and be palatable. An injectable protein solution does not face those challenges. It just needs to keep the protein stable, at the right pH, and at a viscosity that allows injection.

That minimalism has a clinical upside. Fewer ingredients mean fewer potential sources of allergic reactions or sensitivities. It also means fewer variables for quality-control teams to manage, which is important because monoclonal antibodies are manufactured in living cell cultures and are far more sensitive to their chemical environment than a small-molecule pill.

Polysorbate 80 and Injection-Site Reactions

Among the excipients, polysorbate 80 gets the most attention from both patients and researchers. Polysorbates are found in many biologic drugs, foods, and cosmetics, and the vast majority of people tolerate them without issue. However, case reports have documented that biologic agents containing polysorbates can trigger delayed local skin reactions at previous injection sites, not just the current one.5PubMed Central. Delayed local reaction at a previous injection site reaction with dupilumab These are not classic immediate allergic reactions. They tend to show up as redness, swelling, or itching days after an injection, sometimes at a spot you used weeks earlier.

This does not mean polysorbate 80 is dangerous. Injection-site reactions with Dupixent are common and typically mild, and they can have multiple causes beyond the excipient, including the needle itself, the injection technique, or the protein. But if you notice a pattern of reactions, particularly at old injection sites rather than the newest one, mentioning it to your doctor is worthwhile. In rare situations it could prompt a look at whether polysorbate sensitivity is involved.

What the Drug Does to Inflammatory Markers

Since you are injecting dupilumab specifically to block type 2 inflammation, it is worth understanding how researchers confirm it is working at the molecular level. Clinical trials in adults and children with moderate-to-severe asthma have shown that dupilumab treatment leads to rapid and sustained reductions in type 2 inflammatory biomarkers.6PubMed. Dupilumab Efficacy in Patients with Uncontrolled, Moderate-to-Severe Allergic Asthma Two markers in particular drop substantially: total immunoglobulin E (IgE), which is an antibody involved in allergic responses, and fractional exhaled nitric oxide (FeNO), a gas your airways produce in higher amounts when they are inflamed.

In a study of asthma patients treated for a year, dupilumab significantly reduced both FeNO and total IgE compared to placebo, and the effect held regardless of how many different allergens a patient was sensitized to.7PubMed Central. Dupilumab Efficacy in Patients with Uncontrolled Moderate-to-Severe Type 2 Asthma Regardless of Perennial Aeroallergen Sensitization In children treated with dupilumab for asthma, the pattern was similar: total IgE dropped by roughly 79% from baseline over a year, FeNO fell meaningfully, and the inflammatory chemokine TARC also declined.8PubMed. Dupilumab pharmacokinetics and effect on type 2 biomarkers in children with moderate-to-severe asthma These biomarker reductions are consistent with the mechanism described earlier: by blocking the IL-4 receptor, dupilumab shuts down the signaling cascade that drives IgE production and airway inflammation.

For patients, these numbers matter beyond academic interest. Doctors sometimes track IgE or FeNO to gauge whether Dupixent is working, particularly in asthma, where symptom improvement alone can be hard to measure precisely. A large drop in these markers is evidence the drug is doing what its formulation was designed to do.

Prefilled Syringe vs. Autoinjector

Dupixent is available in two delivery formats: a prefilled syringe and an autoinjector pen. The active and inactive ingredients inside are identical, but the experience of injecting differs. The prefilled syringe allows you to control the speed of the injection manually, visually confirm that the full dose has been delivered, and adjust your grip. The autoinjector conceals the needle, fires automatically with a button press, and delivers the dose more quickly, which appeals to people who dislike needles or have dexterity issues. Both formats include needle-safety features that cover the needle after injection to prevent accidental sticks.

From an ingredient and efficacy standpoint, there is no meaningful difference between the two. Injection-site reactions are similar regardless of which format you use. The choice is purely about comfort and preference, and some people switch between formats depending on the situation, using the syringe when a caregiver is administering the injection and the autoinjector when self-injecting.

Why Storage Conditions Matter for the Formulation

Dupixent’s prescribing information calls for refrigerated storage between 2°C and 8°C (about 36°F to 46°F), and forbids freezing. These are not arbitrary rules. The carefully balanced excipient system in the formulation has limits. Research using biophysical testing methods has shown that dupilumab in its commercial formulation undergoes concentration-dependent, reversible self-association under normal conditions, meaning molecules loosely cluster together and separate again. That is expected and harmless. However, exposure to elevated temperatures causes irreversible aggregation, where the protein clumps permanently and cannot return to its functional shape.9PubMed Central. In-situ biophysical characterization of high-concentration protein formulations using wNMR

Freeze-thaw cycles tell a slightly different story. When dupilumab is frozen and then thawed, aggregation does occur, but it is gradually reversible, meaning the protein can recover its proper structure over time if handled correctly.9PubMed Central. In-situ biophysical characterization of high-concentration protein formulations using wNMR That said, the prescribing label still instructs you not to freeze the product, because repeated freeze-thaw cycles could push the protein past the point of recovery, and because there is no practical way for a patient at home to verify the protein has fully recovered.

The sucrose in the formulation is there partly to help with this. Sugar molecules act as a kind of molecular cushion during temperature swings, filling the space around the protein and discouraging unfolding. The histidine buffer system also helps because maintaining pH stability during temperature changes prevents the kind of charge shifts on the protein surface that promote aggregation. Every ingredient on the label, in other words, is there partly because of what happens when storage conditions are not perfect.

The Container Also Matters

One thing the ingredient list does not capture is the interaction between the formulation and the container it sits in. Prefilled syringes are typically made from glass, and the rubber components (plunger stopper, needle shield) can leach trace chemicals into the solution over time. Research into prefilled-syringe drug products has highlighted that these extractables and leachables can accumulate and potentially interact with the drug’s ingredients, affecting stability and, in theory, safety or efficacy.10Expert Opinion on Drug Delivery. Extractables and leachables considerations for prefilled syringes For commercially approved products like Dupixent, extensive testing has already been done to ensure these interactions stay within acceptable limits, but it is one reason why you should not use a syringe that has been stored outside its recommended conditions or past its expiration date.

Worth noting for anyone with a latex allergy: the needle cap of the Dupixent prefilled syringe contains dry natural rubber, which is a derivative of latex. This is listed in the prescribing information, but it is easy to overlook. If you have a known latex sensitivity, let your healthcare provider know before your first injection. The autoinjector pen may be a preferable option in that case, though you should confirm the specific device details with your pharmacist since formulations and device components can change between product updates.

Excipient Awareness and Switching Biologics

If you are switching from another biologic medication to Dupixent, or adding Dupixent to an existing regimen, the excipient list is worth comparing. Research has emphasized the importance of clinical awareness of inactive ingredients in biologics, because patients who have had reactions to one biologic may be reacting to a shared excipient rather than the active antibody itself.4PubMed Central. Biologic excipients: Importance of clinical awareness of inactive ingredients Polysorbate 80, for example, appears in many injectable biologics. If you experienced injection-site reactions on a previous biologic that also contained polysorbate 80, that pattern is worth mentioning to your prescriber before starting Dupixent.

Conversely, if you tolerated a previous biologic well, checking whether its excipient profile overlaps with Dupixent’s can offer some reassurance. The histidine-arginine-sucrose-polysorbate combination in Dupixent is a common modern formulation platform, so many newer antibody drugs share several of these same inactive ingredients. That means a history of good tolerance with other biologics is, in many cases, a reasonable predictor that the excipients in Dupixent will not cause problems either.